UroGen Pharma (URGN) Gross Profit (2017 - 2026)

UroGen Pharma (URGN) has reported Gross Profit for 10 consecutive years, with $46.8 million the latest figure, recorded in Q1 2026.

• Quarterly Gross Profit rose 161.21% year-over-year to $46.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.2 million (up 53.22% YoY) and the FY2025 annual result came in at $97.3 million, up 19.41% from the prior year.
• Gross Profit advanced to $46.8 million in Q1 2026 per URGN's latest filing, from $34.5 million in the prior quarter.
• Over the last five years, Gross Profit for URGN reached as high as $46.8 million in Q1 2026 and fell as low as $12.0 million in Q1 2022.
• A 5-year average of $20.9 million and a median of $18.7 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2024 — Gross Profit grew 4.0% — and 2026, when it soared 161.21%.
• Year by year, Gross Profit stood at $15.8 million in 2022, then surged by 34.21% to $21.2 million in 2023, then increased by 4.0% to $22.1 million in 2024, then surged by 56.37% to $34.5 million in 2025, then soared by 35.52% to $46.8 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $46.8 million, $34.5 million, and $24.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.